These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 18398147)

  • 1. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study.
    Smith MR; Malkowicz SB; Chu F; Forrest J; Sieber P; Barnette KG; Rodriquez D; Steiner MS
    J Clin Oncol; 2008 Apr; 26(11):1824-9. PubMed ID: 18398147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.
    Smith MR; Morton RA; Barnette KG; Sieber PR; Malkowicz SB; Rodriguez D; Hancock ML; Steiner MS
    J Urol; 2013 Jan; 189(1 Suppl):S45-50. PubMed ID: 23234631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.
    Smith MR; Morton RA; Barnette KG; Sieber PR; Malkowicz SB; Rodriguez D; Hancock ML; Steiner MS
    J Urol; 2010 Oct; 184(4):1316-21. PubMed ID: 20723926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer.
    Smith MR; Malkowicz SB; Brawer MK; Hancock ML; Morton RA; Steiner MS
    J Urol; 2011 Dec; 186(6):2239-44. PubMed ID: 22014807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up.
    Oka R; Utsumi T; Endo T; Yano M; Kamijima S; Kamiya N; Shirai K; Suzuki H
    Int J Clin Oncol; 2016 Apr; 21(2):389-396. PubMed ID: 26296528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study.
    Smith MR; Malkowicz SB; Chu F; Forrest J; Price D; Sieber P; Barnette KG; Rodriguez D; Steiner MS
    J Urol; 2008 Jan; 179(1):152-5. PubMed ID: 18001802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen deprivation therapy improves the in vitro capacity of high-density lipoprotein (HDL) to receive cholesterol and other lipids in patients with prostate carcinoma.
    Albuquerque CP; Freitas FR; Martinelli AEM; Lima JH; Coelho RF; Serrano CV; Nahas WC; Kalil Filho R; Maranhão RC
    Lipids Health Dis; 2020 Jun; 19(1):133. PubMed ID: 32522195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
    Kudlacek S; Puntus T
    Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer.
    Joensuu H; Holli K; Oksanen H; Valavaara R
    Breast Cancer Res Treat; 2000 Oct; 63(3):225-34. PubMed ID: 11110056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial.
    Tominaga T; Kimijima I; Kimura M; Takatsuka Y; Takashima S; Nomura Y; Kasumi F; Yamaguchi A; Masuda N; Noguchi S; Eshima N
    Jpn J Clin Oncol; 2010 Jul; 40(7):627-33. PubMed ID: 20382637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer.
    Saarto T; Blomqvist C; Ehnholm C; Taskinen MR; Elomaa I
    J Clin Oncol; 1996 Feb; 14(2):429-33. PubMed ID: 8636753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study.
    Shien T; Doihara H; Sato N; Anan K; Komaki K; Miyauchi K; Yanagita Y; Fujisawa T; Mitsuyama S; Kanbayashi C; Kusama M; Kimura M; Jinno H; Sano M; Ikeda T
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):269-275. PubMed ID: 29196963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients.
    Salvador C; Planas J; Agreda F; Placer J; Trilla E; Lopez MA; Morote J
    Urol Int; 2013; 90(1):41-4. PubMed ID: 23235105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer.
    Saylor PJ; Morton RA; Hancock ML; Barnette KG; Steiner MS; Smith MR
    J Urol; 2011 Aug; 186(2):482-6. PubMed ID: 21679977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer.
    Morgans AK; Hancock ML; Barnette KG; Steiner MS; Morton RA; Smith MR
    J Urol; 2012 Mar; 187(3):889-93. PubMed ID: 22245322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.
    Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Tomlinson GA; Winquist E
    Ann Intern Med; 2017 Sep; 167(5):341-350. PubMed ID: 28785760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
    Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene.
    Taneja SS; Morton R; Barnette G; Sieber P; Hancock ML; Steiner M
    J Clin Oncol; 2013 Feb; 31(5):523-9. PubMed ID: 23295793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toremifene might improve side effects of ADT.
    Nierengarten MB
    Lancet Oncol; 2007 Apr; 8(4):287. PubMed ID: 17436422
    [No Abstract]   [Full Text] [Related]  

  • 20. Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control.
    Ziaran S; Goncalves FM; Breza J
    World J Urol; 2013 Apr; 31(2):289-92. PubMed ID: 22898989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.